Why 'Difficult-to-Treat' May Replace 'Treatment-Resistant'

Psychiatry Debates Dropping the 'Treatment-Resistant' Label

A commentary published in Psychiatric Times on October 13, 2026, proposes that clinicians retire the term "treatment-resistant depression" (TRD) in favor of "difficult-to-treat depression" (DTD). TRD is the standard clinical label for a major depressive episode that has not improved after two or more adequate trials of antidepressant medication. The original article argues that the word "resistant" can imply a case is nearly untreatable, even though many patients who meet TRD criteria eventually respond once treatment is adjusted or tracked more carefully. The piece connects this proposed shift to measurement-informed care (MIC), a clinical method that uses standardized symptom scales, such as the PHQ-9, at set intervals to decide whether a treatment is working, rather than relying only on a clinician's impression from a single visit.

Why the Wording Matters More Than It Sounds

A label is more than a chart entry. According to the source article, framing a case as "resistant" can shape how both clinicians and patients think about what comes next: some patients hear the term and assume the condition has run out of options, while some clinicians stop systematically testing dose, duration, and adherence once the TRD label is applied. The difficult-to-treat framing is meant to signal the opposite: the case is harder to manage, not biologically closed off to improvement, and the appropriate response is more measurement and more methodical adjustment rather than resignation.

This distinction is not cosmetic for anyone considering ketamine-based treatment. Ketamine troches, a sublingual or buccal compounded dosage form of ketamine held in the mouth to dissolve, are typically introduced after a patient has already accumulated a TRD diagnosis from multiple failed antidepressant trials. If that diagnosis is treated as an endpoint rather than a data point, both patients and prescribers can be tempted to treat a troche regimen as a last resort to be judged on gut feel, rather than one more intervention that should be measured and adjusted using the same rigor applied earlier in treatment.

What Measurement-Informed Care Looks Like With Troches

For readers already using or considering compounded ketamine troches, the practical lesson from this reframing is to insist on the same measurement discipline that measurement-informed care applies to standard antidepressants. That means establishing a baseline score on a validated scale, such as the PHQ-9 for depression severity, before starting a troche protocol, then repeating that same scale at defined intervals, for example before each dosing session or every two weeks, rather than relying on how a patient feels in the moment after dosing.

This matters because troche dosing involves variables that are easy to adjust but hard to evaluate without consistent tracking: sublingual versus buccal hold time, milligram strength per troche, dosing frequency, and the specific compounding pharmacy's formulation. Without a standardized score to compare against, it becomes difficult to tell whether a lack of response reflects the ketamine itself, the delivery method, or a dosing variable that needs adjustment, which is exactly the ambiguity the difficult-to-treat framing is meant to address for oral and IV antidepressant trials alike.

It also gives readers a concrete way to compare troches against other ketamine delivery routes. Patients and prescribers can use the same symptom scale to compare a troche protocol against intravenous infusion, intramuscular injection, oral tablet, or intranasal esketamine, instead of switching formats based on anecdote. That comparison is only meaningful if it uses consistent measurement over time, which is the core practice the source article is urging psychiatry to adopt more broadly.

Questions to Bring to Your Next Visit

Readers evaluating or continuing a ketamine troche regimen can use this terminology debate as a prompt for a more concrete conversation with their prescriber. Useful questions include: Does the clinic use a standardized symptom scale, such as the PHQ-9, at every visit, or only at intake? How many antidepressant trials, and at what dose and duration, counted toward the original treatment-resistant diagnosis? How will troche response specifically be tracked over the coming weeks, separate from how past medications were tracked? And what defined threshold, such as a specific point drop on a symptom scale, will determine whether the current troche dose and frequency should change?

This analysis is based on the terminology discussion in the cited Psychiatric Times commentary and does not reflect a new clinical guideline, FDA action, or insurance policy change. Readers should raise these questions directly with a licensed prescriber managing their ketamine treatment.